BLTE — BELITE BIO, INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1889109 ·
Last close
$157.72
Market Cap
$6.35B
52W High
$200.00
52W Low
$105.88
ADV30
175,242
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -36,910,000 | -30,273,000 | 789,738,000 | — | 18,678,000 |
| Jun 2026 | 0 | — | -34,907,000 | -28,412,000 | 791,582,000 | — | 14,946,000 |
| Mar 2026 | 0 | — | -32,684,000 | -26,938,000 | 811,271,000 | — | 15,483,000 |
| Dec 2025 | 0 | — | -28,077,000 | -25,324,000 | 780,556,000 | 352,932,000 | 10,070,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,385,000
Investing CF
$-303,734,000
Financing CF
$510,118,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.73
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-185,258,000
Inventory
—
Receivables
$718,000
ST Investments
$139,490,000
EBIT TTM
$-112,087,000
Pretax Income TTM
$-102,309,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -84,208,000 | -77,611,000 | 780,556,000 | 10,070,000 | 770,486,000 | -36,988,000 |
| Dec 2024 | 0 | -39,996,000 | -36,144,000 | 152,132,000 | 6,311,000 | 145,821,000 | -29,234,000 |
| Dec 2023 | 0 | -31,668,000 | -31,632,000 | 94,642,000 | 4,211,000 | 90,431,000 | -29,837,000 |
| Dec 2022 | 0 | -12,821,000 | -12,648,000 | 44,273,000 | 2,772,000 | 41,501,000 | -11,458,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.26
Max Pain — expiry 2027-06-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $105.00 · spot: $156.23 · call volume: 36 · put volume: 0Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | $6.53B | $96.32 | — |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $6.08B | $42.99 | — |
| MIRM | Mirum Pharmaceuticals, Inc. | $6.00B | $91.95 | — |
| LGND | LIGAND PHARMACEUTICALS INC | $5.86B | $293.81 | — |
| AXSM | Axsome Therapeutics, Inc. | $7.15B | $135.95 | — |
News headlines (Yahoo Finance, 1h cache)
Belite Bio (BLTE) Q3 2026 Earnings Call Transcript
2026-11-13 07:02 · Yahoo
What Belite Bio (BLTE) Said on Its Q3 Earnings Call
2026-11-13 02:14 · Yahoo
Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
2026-11-12 11:00 · Yahoo
Belite Bio (BLTE) Stock May Trade Above Fair Value On Book Value
2026-11-10 06:11 · Yahoo
Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
2026-11-05 13:00 · Yahoo
Belite Bio Stock In Focus After Stargardt Drug Filings In Three Markets
2026-10-17 10:13 · Yahoo
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
2026-10-14 20:00 · Yahoo
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
2026-10-01 12:00 · Yahoo
Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross
2026-09-09 13:55 · Yahoo
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease
2026-09-03 04:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.